Table 2.

Occurrence of hepatocellular carcinoma (HCC) in patients with direct-acting antiviral (DAA) treatment and sustained virological response (SVR) [18–35]

Authors (year) [references]	Total SVR patients (n)	Observation periods (mean months post-DAA initiation)	Patients with HCC occurrence [n (%)]	Annual incidence of HCC (%/year)
Minami et al. (2016) [18]	22	5.8	4 (18)	37.2
Reig et al. (2016) [19]	58	5.7	16 (27.6)	58.1
Torres et al. (2016) [20]	84	12	0 (0)	0
Conti et al. (2016) [21]	403	9	26 (6.5)	8.7
Kolly et al. (2017) [22]	47	12	27 (57.4)	57.4
Cardoso et al. (2017) [23]	54	18	4 (7.4)	4.9
Calleja et al. (2017) [24]	70	12	21 (30)	30
Ikeda et al. (2017) [25]	155	12	47 (30.2)	30.2
Mettke et al. (2017) [26]	158	17.5	6 (3.8)	2.61
Nakao et al. (2017) [27]	242	6	6 (2.5)	5.0
Nagata et al. (2017) [28]	729	24.6	29 (4.0)	1.95
Kanwal et al. (2017) [29]	19,518	15.8	183 (0.9)	0.68
Ioannou et al. (2017) [30]	19,909	18	280 (1.4)	0.93
Cabibbo et al. (2018) [31]	143	12	24 (16.8)	16.8
Ooka et al. (2018) [32]	864	15	41 (4.7)	3.76
Reddy et al. (2018) [33]	893	36	16 (1.8)	0.60
Ogawa et al. (2018) [34]	1675	17	46 (2.7)	1.91
Calvaruso et al. (2018) [35]	2140	14	64 (3.0)	2.57
Total	47,164	14.6 (5.7–36)	840 (1.8)	14.6 (0–58.1)

n number